Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Hepatitis C virus intrinsic molecular determinants may contribute to the development of cholestatic hepatitis after liver transplantation

  • Gambato, Martina
  • Gregori i Font, Josep|||0000-0002-4253-8015
  • Quer, Josep|||0000-0003-0014-084X
  • Koutsoudakis, George
  • González, Patricia
  • Caro-Pérez, Noelia
  • Garcia-Cehic, D.|||0000-0002-0009-038X
  • García-González, Neris
  • González-Candelas, Fernando|||0000-0002-0879-5798
  • Ignacio Esteban, Juan
  • Crespo, Gonzalo|||0000-0002-1178-4897
  • Navasa, Miquel|||0000-0002-3130-9604
  • Forns, Xavier|||0000-0002-8188-1764
  • Pérez-Del-Pulgar, Sofía
Cholestatic hepatitis C (CHC) is a severe form of hepatitis C virus (HCV) infection recurrence that leads to high graft loss rates early after liver transplantation (LT). To investigate the pathogenic mechanisms of CHC, we analysed HCV quasispecies in CHC patients compared to a control group (mild hepatitis C recurrence) by deep pyrosequencing. At the time of LT, NS5B quasispecies complexity was similar between the two groups but, after LT, it decreased more sharply in CHC patients than in the control group. Interestingly, the major variant before LT propagated efficiently and remained as the dominant sequence after LT in 62% of CHC patients versus 11% of controls (P=0.031). Sequence analysis of the complete nonstructural region in a limited number of patients revealed a potential 12 aa signature specific to the CHC group. These data suggest that intrinsic molecular determinants in the circulating HCV quasispecies may provide a fitness advantage, contributing to the development of CHC.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Neutrophil and monocyte function in patients with chronic hepatitis c undergoing antiviral therapy with regimens containing protease inhibitors with and without interferon

  • Gambato, Martina
  • Caro-Pérez, Noelia
  • González, Patricia
  • Cañete Hidalgo, Nuria|||0000-0001-9501-7590
  • Mariño, Zoe|||0000-0001-6321-9534
  • Lens, Sabela|||0000-0003-4900-411X
  • Bonacci, Martín
  • Bartres, Concepció
  • Sánchez Tapias, José María
  • Carrión Rodríguez, José Antonio|||0000-0001-7191-6081
  • Forns, Xavier|||0000-0002-8188-1764
  • Juan, Manel|||0000-0002-3064-1648
  • Pérez-Del-Pulgar, Sofía
  • Londoño, Maria Carlota|||0000-0002-6533-1586
Real-life data showed an increased incidence of bacterial infections in patients with advanced liver disease receiving a protease inhibitor (PI)-containing antiviral regimen against hepatitis C (HCV). However, the causes of this event are unknown. We hypothesized that PIs might impair innate immune responses through the inhibition of proteases participating in the anti-bacterial functions of neutrophils and monocytes. The aims of the study were to assess phagocytic and oxidative burst capacity in neutrophils and monocytes obtained from patients receiving a PI containing-antiviral regimen, and to determine cytokine secretion after neutrophil stimulation with flagellin. Forty patients with chronic HCV (80% with cirrhosis) were enrolled in the study, 28 received triple therapy (Group A) with pegylated-interferon and ribavirin for 4 weeks followed by the addition of a PI (telaprevir, boceprevir or simeprevir), and 12 patients received an interferon-free regimen (Group B) with simeprevir and sofosbuvir. Phagocytosis and oxidative burst capacity were analyzed by flow cytometry at baseline, week 4, and week 8 of therapy. In neutrophils from Group A patients, oxidative burst rate and oxidative enzymatic activity per cell significantly decreased throughout the study period (p = 0.014 and p = 0.010, respectively). Pairwise comparisons showed a decrease between baseline and week 4 and 8 of therapy. No differences were observed after the introduction of the PI. The oxidative enzymatic activity per cell in monocytes significantly decrease during the study period (p = 0.042) due to a decrease from baseline to week 8 of therapy (p = 0.037) in patients from Group A. None of these findings were observed in Group B patients. Cytokine secretion did not significantly change during the study in both groups. In conclusion, our data suggest that the use interferon (rather than the PI) has a deleterious effect on neutrophil and monocyte phagocytic and oxidative burst capacity in this cohort of patients with HCVrelated advanced liver fibrosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Erratum, Neutrophil and monocyte function in patients with chronic hepatitis C undergoing antiviral therapy with regimens containing protease inhibitors with and without interferon (PLoS ONE (2016) 11:11 (e0166631) DOI: 10.1371/journal.pone.0166631)

  • Gambato, Martina
  • Caro-Pérez, Noelia
  • González, Patricia
  • Cañete Hidalgo, Nuria|||0000-0001-9501-7590
  • Mariño, Zoe|||0000-0001-6321-9534
  • Lens, Sabela|||0000-0003-4900-411X
  • Bonacci, Martín
  • Bartres, Concepció
  • Sánchez Tapias, José María
  • Carrión Rodríguez, José Antonio|||0000-0001-7191-6081
  • Forns, Xavier|||0000-0002-8188-1764
  • Juan, Manel|||0000-0002-3064-1648
  • Pérez-Del-Pulgar, Sofía
  • Londoño, Maria Carlota|||0000-0002-6533-1586
There are errors in the Funding section. The correct funding information is as follows: SPP has received a grant from Instituto de Salud Carlos III, Ministerio de Economía y Competitividad (PI13/00155), co-funded by Fondo Europeo de Desarrollo Regional (FEDER), Unión Europea, Una manera de hacer Europa. XF has received a grant from L' Agència de Gestió d'Ajuts Universitaris i de Recerca (AGAUR) (2014-SGR-605). XF was also supported in part by grant PI15/00151, integrated in Plan Nacional de I+D+I and funded by ISCIII-Subdirección General de Evaluación y el Fondo Europeo de Desarrollo Regional (FEDER-"Una manera de Hacer Europa"). MG was funded with an EASL Entry Level Research Fellowship (Dame Sheila Sherlock EASL Fellowship Programme).